Evidence map›Paper›PMID 32048063›Full record

ReviewCurrent treatment options in oncology2020

Detection of Gene Mutations in Liquid Biopsy of Melanoma Patients: Overview and Future Perspectives.

Nasr Alrabadi, Razan Haddad, Ahmed K Alomari

Abstract readReview
PubMed Publisher
In one paragraph

Review in Current treatment options in oncology, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
0.2field-weighted citation impact, top 54% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed, 4 citations in OpenAlex.

  1. Article
  2. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

3 authors at 2 institutions in 2 countries.

Nasr AlrabadiDepartment of Pharmacology, Faculty of Medicine, Jordan University of Science and Technology, Irbid, 22110, Jordan. nnalrabadi@just.edu.jo.
Razan HaddadDepartment of Pharmaceutical Technology, Faculty of Pharmacy, Jordan University of Science and Technology, Irbid, 22110, Jordan.
Ahmed K AlomariDepartment of Pathology and laboratory Medicine, School of Medicine, Indiana University, Indianapolis, IN, USA.
Jordan University of Science and Technology · JOIndiana University – Purdue University Indianapolis · US

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

opinion statementLiquid biopsies are still far from widely implanted in the clinical arena. Issues related to the added sensitivity of this test beyond conventional methods have not been fully resolved. Additionally, issues related to the specificity of these results especially as many cancers may share common mutation need further investigations. One way to resolve this may include the development and testing of large gene panels to add higher specificity. On the other hand, further studies are needed to support the idea that ctDNA or circulating tumor cells may constitute a better representation of the tumor subpopulation that is capable of metastasizing, which will strongly support its clinical value. Finally, survival studies showing a positive impact of this technology will also justify its widespread implementation in clinical practice.

Indexed as

Biomarkers, TumorLiquid BiopsyMutationCirculating Tumor DNAGenetic Association StudiesGenetic Predisposition to DiseaseHumansMelanomaNeoplastic Cells, CirculatingBiomarkers, TumorCirculating Tumor DNACancer therapyGene mutationsLiquid biopsyMelanoma

Identifiers

PMID32048063
OpenAlexW3006034461

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.